RxDoctor Payments Data

Morgan Campbell, DO

Family Medicine · Aurora, CONPI 1497011431

Payments from drug & device makers

$7,063in general payments, 2019–2025

Across 373 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$799
  • Pfizer$437
  • Lilly USA, LLC$429
  • Vanda Pharmaceuticals Inc.$318
  • Novo Nordisk$310
  • plus $3K from 49 others

What the payments were for

  • Food & beverage$7,036100%
  • Other$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,063 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$54,694
Medicare patients
103
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$55,263
OzempicSemaglutide24$41,248
XeljanzTofacitinib Citrate11$36,441
MounjaroTirzepatide20$24,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$19,303
TrulicityDulaglutide12$19,017
EliquisApixaban13$16,210
JanuviaSitagliptin Phosphate17$14,224
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$14,057
FarxigaDapagliflozin Propanediol11$9,595
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,109
Gabapentin88$2,597
Atorvastatin Calcium242$2,058
Omeprazole85$1,883
Losartan Potassium138$1,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$271$55,26335 claims
PfizerXeljanz, Eliquis$437$52,65124 claims
Lilly USA, LLCMounjaro, Trulicity$429$43,27432 claims
Novo NordiskOzempic$310$41,24824 claims
GSKTrelegy Ellipta, Anoro Ellipta$244$33,36031 claims
MerckJanuvia$95$14,22417 claims
AstraZenecaFarxiga$799$9,59511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →